The SOX2-Interactome in Brain Cancer Cells Identifies the Requirement of MSI2 and USP9X for the Growth of Brain Tumor Cells

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Cox, Jesse L ^a   Wilder, Phillip J ^a   Gilmore, Joshua M ^b,c   Wuebben, Erin L ^a   Washburn, Michael P ^b,c   Rizzino, Angie ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b STOWERS INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUSASHI 1; MUSASHI 2; PROTEINASE; RNA BINDING PROTEIN; TRANSCRIPTION FACTOR SOX2; UBIQUITIN SPECIFIC PROTEASE 9X; UNCLASSIFIED DRUG;

ARTICLE; BRAIN CANCER; CANCER CELL CULTURE; CANCER GROWTH; CELL ENGINEERING; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; GLIOBLASTOMA; MEDULLOBLASTOMA; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEOMICS;

ANIMALS; BRAIN NEOPLASMS; CELL ENGINEERING; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE KNOCKDOWN TECHNIQUES; MICE; PROTEIN BINDING; RNA-BINDING PROTEINS; SOXB1 TRANSCRIPTION FACTORS; UBIQUITIN THIOLESTERASE;

EID: 84877113183     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062857     Document Type: Article

References (56)

1. Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, et al. (2007) Long-term survival with glioblastoma multiforme. Brain 130: 2596-2606.
2. Perek D, Perek-Polnik M, Drogosiewicz M, Dembowska-Baginska B, Roszkowski M, et al. (1998) Risk factors of recurrence in 157 MB/PNET patients treated in one institution. Childs Nerv Syst 14: 582-586.
3. Sutter R, Shakhova O, Bhagat H, Behesti H, Sutter C, et al. (2010) Cerebellar stem cells act as medulloblastoma-initiating cells in a mouse model and a neural stem cell signature characterizes a subset of human medulloblastomas. Oncogene 29: 1845-1856.
4. Gangemi RM, Griffero F, Marubbi D, Perera M, Capra MC, et al. (2009) SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells 27: 40-48.
5. Wang J, Rao S, Chu J, Shen X, Levasseur DN, et al. (2006) A protein interaction network for pluripotency of embryonic stem cells. Nature 444: 364-368.
6. Liang J, Wan M, Zhang Y, Gu P, Xin H, et al. (2008) Nanog and Oct4 associate with unique transcriptional repression complexes in embryonic stem cells. Nat Cell Biol 10: 731-739.
7. van den Berg DL, Snoek T, Mullin NP, Yates A, Bezstarosti K, et al. (2010) An Oct4-centered protein interaction network in embryonic stem cells. Cell Stem Cell 6: 369-381.
8. Pardo M, Lang B, Yu L, Prosser H, Bradley A, et al. (2010) An expanded Oct4 interaction network: Implications for stem cell biology, development, and disease. Cell Stem Cell 6: 382-395.
9. Mallanna SK, Ormsbee BD, Iacovino M, Gilmore JM, Cox JL, et al. (2010) Proteomic analysis of Sox2-associated proteins during early stages of mouse embryonic stem cell differentiation identifies Sox21 as a novel regulator of stem cell fate. Stem Cells 28: 1715-1727.
10. Ding J, Xu H, Faiola F, Ma'ayan A, Wang J, (2012) Oct4 links multiple epigenetic pathways to the pluripotency network. Cell Res 22: 155-167.
11. Gao Z, Cox JL, Gilmore JM, Ormsbee BD, Mallanna SK, et al. (2012) Determination of protein interactome of transcription factor Sox2 in embryonic stem cells engineered for inducible expression of four reprogramming factors. J Biol Chem 287: 11384-11397.
12. Mallanna SK, Rizzino A, (2012) Systems biology provides new insights into the molecular mechanisms that control the fate of embryonic stem cells. J Cell Physiol 227: 27-34.
13. Rizzino A. (2013) The Sox2-Oct4 Connection: Critical players in a much larger interdependent network integrated at multiple levels. Stem Cell, in press.
14. Wuebben EL, Mallanna SK, Cox JL, Rizzino A, (2012) Musashi2 is required for the self-renewal and pluripotency of embryonic stem cells. PloS One 7: e34827.
15. Cox JL, Mallanna SK, Ormsbee BD, Desler M, Wiebe MS, et al. (2011) Banf1 is required to maintain the self-renewal of both mouse and human embryonic stem cells. J Cell Sci 124: 2654-2665.
16. Ito T, Kwon HY, Zimdahl B, Congdon KL, Blum J, et al. (2010) Regulation of myeloid leukaemia by the cell-fate determinant musashi. Nature 466: 765-768.
17. Kharas MG, Lengner CJ, Al-Shahrour F, Bullinger L, Ball B, et al. (2010) Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med 16: 903-908.
18. Griner LN, Reuther GW, (2010) Aggressive myeloid leukemia formation is directed by the musashi 2/numb pathway. Cancer Biol Ther 10: 979-982.
19. Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, et al. (2010) Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 463: 103-107.
20. Perez-Mancera PA, Rust AG, van der Weyden L, Kristiansen G, Li A, et al. (2012) The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature 486: 266-270.
21. Shi D, Grossman SR, (2010) Ubiquitin becomes ubiquitous in cancer: Emerging roles of ubiquitin ligases and deubiquitinases in tumorigenesis and as therapeutic targets. Cancer Biol Ther 10: 737-747.
22. Kingsley-Kallesen M, Luster TA, Rizzino A, (2001) Transcriptional regulation of the transforming growth factor-beta2 gene in glioblastoma cells. In Vitro Cell Dev Biol Anim 37: 684-690.
23. Wiebe MS, Traktman P, (2007) Poxviral B1 kinase overcomes barrier to autointegration factor, a host defense against virus replication. Cell Host Microbe 1: 187-197.
24. Kelly D, Scholtz B, Orten DJ, Hinrichs SH, Rizzino A, (1995) Regulation of the transforming growth factor-beta 2 gene promoter in embryonal carcinoma cells and their differentiated cells: Differential utilization of transcription factors. Mol Reprod Dev 40: 135-145.
25. Zhang Y, Wen Z, Washburn MP, Florens L, (2010) Refinements to label free proteome quantitation: How to deal with peptides shared by multiple proteins. Anal Chem 82: 2272-2281.
26. Elias JE, Haas W, Faherty BK, Gygi SP, (2005) Comparative evaluation of mass spectrometry platforms used in large-scale proteomics investigations. Nat Methods 2: 667-675.
27. Cox JL, Mallanna SK, Luo X, Rizzino A, (2010) Sox2 uses multiple domains to associate with proteins present in Sox2-protein complexes. PloS One 5: e15486.
28. Sanchez-Diaz PC, Burton TL, Burns SC, Hung JY, Penalva LO, (2008) Musashi1 modulates cell proliferation genes in the medulloblastoma cell line daoy. BMC Cancer 8: 280.
29. Muto J, Imai T, Ogawa D, Nishimoto Y, Okada Y, et al. (2012) RNA-binding protein Musashi1 modulates glioma cell growth through the post-transcriptional regulation of notch and PI3 kinase/akt signaling pathways. PloS One 7: e33431.
30. Cheng X, Huber TL, Chen VC, Gadue P, Keller GM, (2008) Numb mediates the interaction between wnt and notch to modulate primitive erythropoietic specification from the hemangioblast. Development 135: 3447-3458.
31. Katoh M, Katoh M, (2006) NUMB is a break of WNT-notch signaling cycle. Int J Mol Med 18: 517-521.
32. Pantaleon M, Kanai-Azuma M, Mattick JS, Kaibuchi K, Kaye PL, et al. (2001) FAM deubiquitylating enzyme is essential for preimplantation mouse embryo development. Mech Dev 109: 151-160.
33. Murray RZ, Jolly LA, Wood SA, (2004) The FAM deubiquitylating enzyme localizes to multiple points of protein trafficking in epithelia, where it associates with E-cadherin and beta-catenin. Mol Biol Cell 15: 1591-1599.
34. Taya S, Yamamoto T, Kanai-Azuma M, Wood SA, Kaibuchi K, (1999) The deubiquitinating enzyme fam interacts with and stabilizes beta-catenin. Genes Cells 4: 757-767.
35. Mouchantaf R, Azakir BA, McPherson PS, Millard SM, Wood SA, et al. (2006) The ubiquitin ligase itch is auto-ubiquitylated in vivo and in vitro but is protected from degradation by interacting with the deubiquitylating enzyme FAM/USP9X. J Biol Chem 281: 38738-38747.
36. Fang X, Yoon JG, Li L, Tsai YS, Zheng S, et al. (2011) Landscape of the SOX2 protein-protein interactome. Proteomics 11: 921-934.
37. Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, et al. (2012) Molecular subgroups of medulloblastoma: The current consensus. Acta Neuropathol123: 465-472.
38. Ringer L, Sirajuddin P, Heckler M, Ghosh A, Suprynowicz F, et al. (2011) VMY-1-103 is a novel CDK inhibitor that disrupts chromosome organization and delays metaphase progression in medulloblastoma cells. Cancer Biol Ther 12: 818-826.
39. Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, et al. (2011) Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 29: 1424-1430.
40. Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein D, et al. (2006) Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 24: 1924-1931.
41. Robinson G, Parker M, Kranenburg TA, Lu C, Chen X, et al. (2012) Novel mutations target distinct subgroups of medulloblastoma. Nature 488: 43-48.
42. Leung C, Lingbeek M, Shakhova O, Liu J, Tanger E, et al. (2004) Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature 428: 337-341.
43. Abdouh M, Facchino S, Chatoo W, Balasingam V, Ferreira J, et al. (2009) BMI1 sustains human glioblastoma multiforme stem cell renewal. J Neurosci 29: 8884-8896.
44. Festa M, Del Valle L, Khalili K, Franco R, Scognamiglio G, et al. (2011) BAG3 protein is overexpressed in human glioblastoma and is a potential target for therapy. Am J Pathol 178: 2504-2512.
45. Huang Q, Zhang QB, Dong J, Wu YY, Shen YT, et al. (2008) Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro. BMC Cancer 8: 304.
46. Eichhorn PJ, Rodon L, Gonzalez-Junca A, Dirac A, Gili M, et al. (2012) USP15 stabilizes TGF-beta receptor I and promotes oncogenesis through the activation of TGF-beta signaling in glioblastoma. Nat Med 18: 429-435.
47. Imai T, Tokunaga A, Yoshida T, Hashimoto M, Mikoshiba K, et al. (2001) The neural RNA-binding protein Musashi1 translationally regulates mammalian numb gene expression by interacting with its mRNA. Mol Cell Biol 21: 3888-3900.
48. Di Marcotullio L, Ferretti E, Greco A, De Smaele E, Po A, et al. (2006) Numb is a suppressor of hedgehog signalling and targets Gli1 for itch-dependent ubiquitination. Nat Cell Biol 8: 1415-1423.
49. de Sousa Abreu R, Sanchez-Diaz PC, Vogel C, Burns SC, Ko D, et al. (2009) Genomic analyses of musashi1 downstream targets show a strong association with cancer-related processes. J Biol Chem 284: 12125-12135.
50. Euskirchen P, Skaftnesmo KO, Huszthy PC, Brekka N, Bjerkvig R, et al. (2011) NUMB does not impair growth and differentiation status of experimental gliomas. Exp Cell Res 317: 2864-2873.
51. Nathan JA, Sengupta S, Wood SA, Admon A, Markson G, et al. (2008) The ubiquitin E3 ligase MARCH7 is differentially regulated by the deubiquitylating enzymes USP7 and USP9X. Traffic 9: 1130-1145.
52. Dupont S, Mamidi A, Cordenonsi M, Montagner M, Zacchigna L, et al. (2009) FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell 136: 123-135.
53. Nagai H, Noguchi T, Homma K, Katagiri K, Takeda K, et al. (2009) Ubiquitin-like sequence in ASK1 plays critical roles in the recognition and stabilization by USP9X and oxidative stress-induced cell death. Mol Cell 36: 805-818.
54. Theard D, Labarrade F, Partisani M, Milanini J, Sakagami H, et al. (2010) USP9x-mediated deubiquitination of EFA6 regulates de novo tight junction assembly. EMBO J 29: 1499-1509.
55. Al-Hakim AK, Zagorska A, Chapman L, Deak M, Peggie M, et al. (2008) Control of AMPK-related kinases by USP9X and atypical lys(29)/lys(33)-linked polyubiquitin chains. Biochem J 411: 249-260.
56. Connolly EC, Freimuth J, Akhurst RJ, (2012) Complexities of TGF-beta targeted cancer therapy. Int J Biol Sci 8: 964-978.